PDF / 71 KB 
collectBayerNews_20080508_0144_en.pdf BayerNews_20080508_0144_en.pdf
International study to evaluate efficacy and safety in treating a leading cause of blindness
Leverkusen, Germany, Montville, NJ and Tarrytown, NY, May 8, 2008 - Bayer
HealthCare AG and development partner Regeneron Pharmaceuticals, Inc.
(NASDAQ:REGN) today announced that the first patient has been dosed in the new
VIEW 2 trial, a second Phase 3 clinical study in a development program
evaluating VEGF Trap-Eye for the treatment of the neovascular form of
age-related macular degeneration (wet AMD), a leading cause of blindness in
adults.
VIEW 2 (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD) will
enroll approximately 1,200 patients in up to 200 centers in Europe, Asia
Pacific, Japan and Latin America. The first Phase 3 trial, VIEW 1, began
enrolling patients in August 2007 in the United States and Canada. Both VIEW 1
and VIEW 2 are designed to evaluate the efficacy and safety of VEGF Trap-Eye
administered by intravitreal injection, at dosing intervals of 4 and 8 weeks.
The development program will include visual acuity endpoints and anatomical
endpoints, including retinal thickness, a measure of disease activity. The
trial is intended to establish non-inferiority of VEGF Trap-Eye with Lucentis®
(ranibizumab) an antiangiogenic agent approved for use in wet AMD in major
markets globally.
Wet AMD accounts for about 90 percent of all severe AMD-related vision loss. It
occurs when abnormal blood vessels in the eye leak fluid and blood into the
macula, the area of the retina that allows for vision of fine details. This can
lead to a rapid loss of central vision with continued progression.
"Results from the Phase 2 study have shown that VEGF Trap-Eye has the potential
to significantly reduce retinal thickness and improve vision," said Kemal
Malik, MD, Head of Global Development and member of the Bayer HealthCare
Executive Committee. "Dosing of the first patient in this confirmatory Phase 3
trial is an important milestone for this compound intended to treat a
devastating ocular disease that impacts millions of people worldwide."
"New therapies are still needed to provide optimal care to those patients with
wet AMD," said George D. Yancopoulos, M.D., Ph.D., President of Regeneron
Research Laboratories. "This global Phase 3 clinical program will provide
additional data to further evaluate the efficacy and safety of VEGF Trap-Eye
using different dosing regimens."
Bayer HealthCare and Regeneron are collaborating on the global development of
VEGF Trap-Eye for treatment of wet AMD, diabetic eye diseases, and other ocular
diseases and disorders. Once approved, Bayer HealthCare will market VEGF
Trap-Eye outside the U.S., where the parties will share equally in profits from
any future sales of VEGF Trap-Eye. Regeneron maintains exclusive rights to VEGF
Trap-Eye in the U.S. VIEW 2 primary analysis results are anticipated in 2011.
About VIEW 2
In the first year, the VIEW 2 study will evaluate the safety and efficacy of
VEGF Trap-Eye at doses of 0.5 milligrams (mg) and 2.0 mg administered at 4-week
intervals and 2.0 mg at an 8-week dosing interval, including one additional 2.0
mg dose at week four. Patients randomized to the ranibizumab arm of the trial
will receive a 0.5 mg dose every 4 weeks. After the first year of treatment,
patients will continue to be followed and treated for another year on a
flexible, criteria-based extended regimen with a dose administered at least
every 12 weeks, but not more often than every 4 weeks until the end of the
study.
The primary endpoint of the study is the proportion of patients treated with
VEGF Trap-Eye who maintain vision at the end of one year, compared to
ranibizumab patients. Visual acuity is defined as the total number of letters
read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart,
a standard chart used in research to measure visual acuity. Maintenance of
vision is defined as losing fewer than three lines (equivalent to 15 letters)
on the ETDRS chart. Key secondary endpoints include the mean change from
baseline in visual acuity as measured by ETDRS and the proportion of patients
who gained at least 15 letters of vision at week 52.
Phase 2 Clinical Data
In a Phase 2 trial in 157 patients, announced in October 2007 at the Retina
Society Conference in Boston, VEGF Trap-Eye met both primary and secondary key
endpoints: a statistically significant reduction in retinal thickness (a
measure of disease activity) after 12 weeks of treatment compared with baseline
and a statistically significant improvement from baseline in visual acuity
(ability to read letters on an eye chart).
About VEGF Trap-Eye
Vascular endothelial growth factor (VEGF) is a naturally occurring protein in
the body whose normal role is to trigger the formation of new blood vessels
(angiogenesis) to support the growth of the body's tissues and organs. It has
also been associated with the abnormal growth and fragility of new blood
vessels in the eye, which lead to the development of wet AMD. VEGF Trap-Eye is
a fully human, soluble VEGF receptor fusion protein that binds all forms of
VEGF-A along with the related placental growth factor (PIGF) and VEGF-B. VEGF
Trap-Eye is a specific and highly potent blocker of these growth factors.
Blockade of VEGF can prevent abnormal blood vessel formation as well as
vascular leak and has proven beneficial in the treatment of wet AMD.
About Wet AMD
Age-related macular degeneration (AMD) is a leading cause of acquired
blindness. Macular degeneration is diagnosed as either dry (non-exudative) or
wet (exudative). In wet AMD, new blood vessels grow beneath the retina and leak
blood and fluid. This leakage causes disruption and dysfunction of the retina
creating blind spots in central vision, and it can account for blindness in wet
AMD patients. Wet AMD is the leading cause of blindness for people over the age
of 65 in the U.S. and Europe.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of
health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary
of Bayer AG, is one of the world's leading, innovative companies in the
healthcare and medical products industry and is based in Leverkusen, Germany.
The company combines the global activities of the Animal Health, Consumer Care,
Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business
operates under the name Bayer Schering Pharma AG. Bayer HealthCare's aim is to
discover and manufacture products that will improve human and animal health
worldwide. Find more information at www.bayerhealthcare.com.
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company.
Its research and business activities are focused on the following areas:
Diagnostic Imaging, General Medicine, Specialty Medicine and Women's
Healthcare. With innovative products, Bayer Schering Pharma aims for leading
positions in specialized markets worldwide. Using new ideas, Bayer Schering
Pharma aims to make a contribution to medical progress and strives to improve
the quality of life. Find more information at www.bayerscheringpharma.de.
About Regeneron
Regeneron is a fully integrated biopharmaceutical company that discovers,
develops, and commercializes medicines for the treatment of serious medical
conditions. In addition to ARCALYSTTM (rilonacept) Injection for Subcutaneous
Use, its first commercialized product, Regeneron has therapeutic candidates in
clinical trials for the potential treatment of cancer, eye diseases, and
inflammatory diseases, and has preclinical programs in other diseases and
disorders. Additional information about Regeneron and recent news releases are
available on Regeneron's Web site at www.regeneron.com.
(Note: Lucentis® is a registered trademark of Genentech, Inc.)
